Nicole Murphy's most recent trade in Biogen Inc was a trade of 2,272 Common Stock done . Disclosure was reported to the exchange on Feb. 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 2,272 | 14,725 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 2,272 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 142.54 per share. | 10 Feb 2025 | 670 | 14,055 (0%) | 0% | 142.5 | 95,502 | Common Stock |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 14,050 | 14,050 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 2,102 | 2,102 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 2,102 | 11,736 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 1,940 | 13,056 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 1,940 | 3,880 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 141.35 per share. | 06 Feb 2025 | 620 | 11,116 (0%) | 0% | 141.4 | 87,637 | Common Stock |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 141.35 per share. | 06 Feb 2025 | 603 | 12,453 (0%) | 0% | 141.3 | 85,234 | Common Stock |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 240 | 9,751 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 240 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 214.83 per share. | 01 Apr 2024 | 117 | 9,634 (0%) | 0% | 214.8 | 25,135 | Common Stock |
| Biogen Inc | Murphy Nicole | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 856 | 9,623 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Murphy Nicole | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 856 | 0 | - | - | Performance Stock Unit | |
| Biogen Inc | Murphy Nicole | Head of Pharm Ops and Tech | Other type of transaction at price $ 0.00 per share. | 16 Feb 2024 | 504 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 219.08 per share. | 16 Feb 2024 | 414 | 9,209 (0%) | 0% | 219.1 | 90,699 | Common Stock |
| Biogen Inc | Murphy Nicole | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 404 | 504 | - | - | Restricted Stock Unit | |
| Biogen Inc | Murphy Nicole | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 404 | 9,613 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 219.08 per share. | 16 Feb 2024 | 196 | 9,417 (0%) | 0% | 219.1 | 42,940 | Common Stock |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 2,272 | 9,528 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Murphy Nicole | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 2,272 | 2,272 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 240.98 per share. | 09 Feb 2024 | 761 | 8,767 (0%) | 0% | 241.0 | 183,386 | Common Stock |
| Biogen Inc | Murphy Nicole | Head of Pharm Ops and Tech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 5,820 | 5,820 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2024 | 2,101 | 7,894 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2024 | 2,101 | 4,204 | - | - | Restricted Stock Unit | |
| Biogen Inc | Murphy Nicole | Head of Pharm Ops and Tech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 240.30 per share. | 07 Feb 2024 | 638 | 7,256 (0%) | 0% | 240.3 | 153,311 | Common Stock |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2024 | 856 | 856 | - | - | Performance Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 239 | 5,818 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 239 | 240 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 278.03 per share. | 31 Mar 2023 | 116 | 5,702 (0%) | 0% | 278.0 | 32,251 | Common Stock |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2023 | 480 | 5,579 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2023 | 480 | 1,334 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Other type of transaction at price $ 0.00 per share. | 17 Feb 2023 | 426 | 908 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 278.38 per share. | 17 Feb 2023 | 233 | 5,099 (0%) | 0% | 278.4 | 64,863 | Common Stock |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 2,271 | 4,544 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 2,271 | 6,379 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 286.30 per share. | 10 Feb 2023 | 685 | 5,694 (0%) | 0% | 286.3 | 196,116 | Common Stock |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 286.30 per share. | 10 Feb 2023 | 537 | 5,497 (0%) | 0% | 286.3 | 153,743 | Common Stock |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Other type of transaction at price $ 0.00 per share. | 10 Feb 2023 | 416 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 340 | 416 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 340 | 6,034 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 286.30 per share. | 10 Feb 2023 | 165 | 5,332 (0%) | 0% | 286.3 | 47,240 | Common Stock |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 6,305 | 6,305 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 1,340 | 4,108 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 131 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 131 | 2,807 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.90 per share. | 02 Dec 2022 | 39 | 2,768 (0%) | 0% | 298.9 | 11,657 | Common Stock |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2022 | 825 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2022 | 825 | 2,919 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Other type of transaction at price $ 0.00 per share. | 01 Aug 2022 | 299 | 255 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2022 | 255 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2022 | 255 | 2,170 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 209.26 per share. | 01 Aug 2022 | 243 | 2,676 (0%) | 0% | 209.3 | 50,850 | Common Stock |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 209.26 per share. | 01 Aug 2022 | 76 | 2,094 (0%) | 0% | 209.3 | 15,904 | Common Stock |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 239 | 479 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 239 | 1,896 (0%) | 0% | - | Common Stock | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 210.65 per share. | 01 Apr 2022 | 84 | 1,812 (0%) | 0% | 210.7 | 17,695 | Common Stock |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Other type of transaction at price $ 0.00 per share. | 18 Feb 2022 | 535 | 1,814 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 371 | 2,349 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 371 | 1,767 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 209.79 per share. | 18 Feb 2022 | 110 | 1,657 (0%) | 0% | 209.8 | 23,077 | Common Stock |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Other type of transaction at price $ 0.00 per share. | 12 Feb 2022 | 489 | 756 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2022 | 263 | 1,245 | - | - | Restricted Stock Unit | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2022 | 263 | 1,488 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Payment of exercise price or tax liability using portion of securities received from the company at price $ 214.59 per share. | 12 Feb 2022 | 92 | 1,396 (0%) | 0% | 214.6 | 19,742 | Common Stock |
| Biogen Inc | Nicole Murphy | Head of Pharm Ops and Tech | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 6,815 | 6,815 | - | - | Restricted Stock Unit |